

Table S1. Clinical and morphological features of 44 MDA PCa PDXs

Patient ID	PDX name is "MDA PCa + the alphanumeric string below"	Race	Treatment Status	Last Treatment Category	Prior Treatments	Primary, Bone or Other Metastatic Site	Tumor Site	Morphology of PDX	**Growth rate (days)	Publications
MDA PCa Pat-117	117-9	Hispanic	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Adenocarcinoma	79	PMID: 22156612; 22245216; 24847116; 22363599; 30073676; 29138344; 26890396; 36461624; 35805010; 32576626
MDA PCa Pat-118	118b	White	mCRPC	Chemotherapy	1st Generation ADT	Bone	Bone	Adenocarcinoma	32	PMID: 25527621; 22457212; 22134886; 21670081; 21343372; 20564322; 25832466; 25762070; 25186177; 24779589; 22457212; 22298898; 21575865; 18618013; 27791181; 26096936; 26096936; 26272062; 26599623; 26530902; 30682644; 30555629; 30073676; 29887238; 29769196; 29138344; 26890396; 26792867; 28586644; 26272062; 35805010; 32576626; 33753455
MDA PCa Pat-133	133-4	White	mCRPC	Chemotherapy	1st Generation ADT	Bone	Bone	Adenocarcinoma	52	PMID: 23300537; 21670081; 26800435; 24847116; 21575865; 28228262; 28536297; 30287808; 27748439; 30555629; 30073676; 29138344; 29748904; 35805010; 32576626
MDA PCa Pat-144	144-13	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Neuroendocrine Carcinoma	38	PMID: 21456067; 24847116; 22156612; 26272062; 30287808; 30555629; 30073676; 29138344; 26890396; 29748904; 26272062; 35805010; 32576626; 35385726
MDA PCa Pat-144	144-4	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	*Bladder	Neuroendocrine Carcinoma	33	PMID: 32576626; 35385726
MDA PCa Pat-146	146-10	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	*Bladder	Neuroendocrine Carcinoma	76	PMID: 24847116; 22156612; 30073676; 29138344; 26890396; 26792867; 35805010; 32576626; 34738088
MDA PCa Pat-146	146-12	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	*Bladder	Adenocarcinoma	88	PMID: 34937944; 32576626; 34738088
MDA PCa Pat-150	150-7	White	mCRPC	Chemotherapy	1st Generation ADT	Bone	Bone	Neuroendocrine Carcinoma	45	PMID: 30073676; 29138344; 32576626
MDA PCa Pat-152	152-1	White	mCRPC	1st Generation ADT	1st Generation ADT	Other Metastatic Site	Brain	*Adenocarcinoma	40	PMID: 30555629; 29138344; 35805010; 32576626
MDA PCa Pat-153	153-7	White	mCRPC	1st Generation ADT	1st Generation ADT	Other Metastatic Site	Thyroid	Adenocarcinoma	88	PMID: 24847116; 22133722; 30073676; 29138344; 32576626
MDA PCa Pat-155	155-2	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	*Bladder	Neuroendocrine Carcinoma	64	PMID: 24847116; 22156612; 29138344; 26890396; 29748904; 35805010; 32576626; 35385726
MDA PCa Pat-163	163-A	White	mCRPC	1st Generation ADT	1st Generation ADT	Primary	Prostate	Adenocarcinoma	55	PMID: 35385726; 35805010
MDA PCa Pat-173	173-2	White	Naive	Naive		Primary	Prostate	Adenocarcinoma	83	PMID: 24847116; 22156612; 30073676; 30555629; 30073676; 35805010; 32576626; 37018402
MDA PCa Pat-174	174-6	Black	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Adenocarcinoma	78	
MDA PCa Pat-175	175-6	Hispanic	mCRPC	Chemotherapy	1st Generation ADT	Other Metastatic Site	Testis	Adenocarcinoma	66	PMID: 30073676; 32576626; 37018402
MDA PCa Pat-177	177-8	White	mCRPC	1st Generation ADT	1st Generation ADT	Primary	Prostate	Poorly Differentiated Carcinoma	46	PMID: 30073676; 35805010; 32576626
MDA PCa Pat-178	178-11	White	NADT	1st Generation ADT	1st Generation ADT	Primary	Prostate	Adenocarcinoma	94	PMID: 30073676; 35805010; 32576626
MDA PCa Pat-180	180-30	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Adenocarcinoma	47	PMID: 22245216; 24847116; 22156612; 30073676; 29769196; 29748904; 26272062; 35805010; 32576626
MDA PCa Pat-183/203	183-A	White	Naive	Naive		Bone	Bone	Adenocarcinoma	67	PMID: 24779589; 22133722; 30682644; 30555629; 30073676; 29887238; 29138344; 28166537; 35805010; 32576626; 34584218
MDA PCa Pat-200	200-1	White	mCRPC	1st Generation ADT	1st Generation ADT	Bone	Bone	Adenocarcinoma	44	
MDA PCa Pat-183/203	203-A	White	mCRPC	1st Generation ADT	1st Generation ADT	Bone	Bone	Adenocarcinoma	93	PMID: 30073676; 35805010; 34584218
MDA PCa Pat-250	250-15	White	NADT	1st Generation ADT	1st Generation ADT	Other Metastatic Site	Adrenal Gland	*Adenocarcinoma	86	PMID: 36100698; 36100698
MDA PCa Pat-265	265-8	White	mCRPC	Chemotherapy	2nd Generation ADT	Primary	Prostate	Adenocarcinoma	40	PMID: 30073676; 35805010
MDA PCa Pat-266	266-A	White	mCRPC	Chemotherapy	1st Generation ADT	Other Metastatic Site	Serous Cavity	Adenocarcinoma	54	PMID: 30073676; 35805010
MDA PCa Pat-270	270-A	White	NADT	1st Generation ADT	1st Generation ADT	Bone	Bone	Adenocarcinoma	80	PMID: 30073676; 35805010
MDA PCa Pat-273	273-A	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Other Metastatic Site	Lymph Node	Neuroendocrine Carcinoma	63	PMID: 30073676; 35805010
MDA PCa Pat-274	274-2	White	mCRPC	Chemotherapy	2nd Generation ADT	Bone	Bone	Adenocarcinoma	47	
MDA PCa Pat-277	277-6	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Other Metastatic Site	Lymph Node	Neuroendocrine Carcinoma	35	PMID: 30555629
MDA PCa Pat-280/306	280-9	White	Naive	Naive		Other Metastatic Site	Lymph Node	Adenocarcinoma	35	
MDA PCa Pat-285	285-3	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Primary	*Bladder	Adenocarcinoma	124	
MDA PCa Pat-280/306	306-14	White	mCRPC	1st Generation ADT	1st Generation ADT	Primary	Prostate	Adenocarcinoma	97	
MDA PCa Pat-312	312-7	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Neuroendocrine Carcinoma	58	PMID: 35805010
MDA PCa Pat-315	315-8	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Primary	Prostate	Poorly Differentiated Carcinoma	75	
MDA PCa Pat-316	316-1	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Bone	Bone	Adenocarcinoma	55	
MDA PCa Pat-316	316-2	White	mCRPC	2nd Generation ADT	2nd Generation ADT	Other Metastatic Site	CTC	Adenocarcinoma	43	
MDA PCa Pat-320	320-1	White	mCRPC	1st Generation ADT	1st Generation ADT	Other Metastatic Site	CTC	Adenocarcinoma	48	
MDA PCa Pat-322	322-2	Black	NADT	1st Generation ADT	1st Generation ADT	Primary	Prostate	Adenocarcinoma	101	
MDA PCa Pat-328	327-2	White	mCRPC	Chemotherapy	2nd Generation ADT	Other Metastatic Site	CTC	Adenocarcinoma	54	
MDA PCa Pat-328	328-5	White	CRPC	1st Generation ADT	1st Generation ADT	Primary	*Bladder	Neuroendocrine Carcinoma	55	PMID: 35805010
MDA PCa Pat-337	337-A	Black	mCRPC	1st Generation ADT	1st Generation ADT	Other Metastatic Site	Liver	Neuroendocrine Carcinoma	51	PMID: 34636746; 36461624
MDA PCa Pat-342/355	342-B	White	mCRPC	Chemotherapy	1st Generation ADT	Primary	Prostate	Sarcomatoid Carcinoma	32	
MDA PCa Pat-352	352-8	Black	mCRPC	2nd Generation ADT	2nd Generation ADT	Other Metastatic Site	Lymph Node	Adenocarcinoma	50	
MDA PCa Pat-342/355	355-9	White	mCRPC	Chemotherapy	2nd Generation ADT	Primary	*Bladder	Sarcomatoid Carcinoma	25	
MDA PCa Pat-377	377-1	Black	mCRPC	Chemotherapy	2nd Generation ADT	Other Metastatic Site	Brain	Adenocarcinoma	60	

PDX, patient-derived xenograft; mCRPC, metastatic castration-resistant prostate cancer; ADT, androgen deprivation therapy; NADT, On Neoadjuvant androgen deprivation therapy; CTC, circulating tumor cells; *, Direct extension of prostate cancer; †, these PDX have ductal features

PDXs with same Patient ID are derived from different areas of the same tumor at the same time. All morphologies reflect the patient sample of origin (PMID:32576626)

** Growth rate is calculated based on the number of days that it takes a 0.5 cm³ piece of PDX tissue implanted subcutaneously to develop into a tumor that is 1.5 cm in its largest diameter. This data is not listed for most archived models as they can no longer be grown.